Home›Stock Screener›Ajanta Pharma›Intrinsic Value

Ajanta Pharma Intrinsic Value

Ajanta Pharma intrinsic value. Ajanta Pharma (AJANTPHARM) median intrinsic value is ₹2734.16 from 10 valuation models (range ₹981–₹6541), vs current price ₹3270.30 — -16.4% downside (Trading Above Median Value), margin of safety -19.6%. For current market price and key ratios, visit Ajanta Pharma stock price NSE.

Market Price (CMP)
₹3270.30
Primary Intrinsic Value
₹2734.16
Market Cap
₹8176 Cr
-16.4% Downside
Median Value
₹2734.16
Value Range
₹981 - ₹6541
Assessment
Trading Above Median Value
Safety Margin
-19.6%

AJANTPHARM Valuation Methods Summary — DCF, Graham Number & P/E

Ajanta Pharma intrinsic value across 10 models vs current price ₹3270.30 — upside/downside and value range per method. Analyse AJANTPHARM shareholding pattern to track promoter, FII and institutional holdings.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹2734.16 ₹2187.33 - ₹3280.99 -16.4% EPS: ₹124.28, Sector P/E: 22x
Book Value Method asset ₹3621.60 ₹3259.44 - ₹3983.76 +10.7% Book Value/Share: ₹1810.80, P/B: 2.0x
Revenue Multiple Method revenue ₹5862.40 ₹5276.16 - ₹6448.64 +79.3% Revenue/Share: ₹2931.20, P/S: 2.0x
EBITDA Multiple Method earnings ₹6540.60 ₹5886.54 - ₹7194.66 +100.0% EBITDA: ₹2340.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹1964.45 ₹1571.56 - ₹2357.34 -39.9% CF Growth: 5.0%, Discount: 15%
PEG Ratio Method growth ₹981.09 ₹882.98 - ₹1079.20 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹1920.13 ₹1728.12 - ₹2112.14 -41.3% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹6540.60 ₹5886.54 - ₹7194.66 +100.0% ROE: 34.3%, P/E Multiple: 16x
Graham Defensive Method conservative ₹2250.23 ₹2025.21 - ₹2475.25 -31.2% EPS: ₹124.28, BVPS: ₹1810.80
Dividend Yield Method dividend ₹1120.00 ₹1008.00 - ₹1232.00 -65.8% DPS: ₹28.00, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

AJANTPHARM Intrinsic Value vs Market Price — All Valuation Models

Ajanta Pharma fair value range ₹981–₹6541 vs current market price ₹3270.30 across 10 valuation models. Browse Ajanta Pharma annual reports for revenue, profit, balance sheet and cash flow data.

AJANTPHARM Intrinsic Value Analysis — Undervalued or Overvalued?

Ajanta Pharma median intrinsic value ₹2734.16, current price ₹3270.30 — Trading Above Median Value by 16.4%, margin of safety -19.6%.

What is the intrinsic value of AJANTPHARM?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Ajanta Pharma (AJANTPHARM) is ₹2734.16 (median value). With the current market price of ₹3270.30, this represents a -16.4% variance from our estimated fair value.

The valuation range spans from ₹981.09 to ₹6540.60, indicating ₹981.09 - ₹6540.60.

Is AJANTPHARM undervalued or overvalued?

Based on our multi-method analysis, Ajanta Pharma (AJANTPHARM) appears to be trading above median value by approximately 16.4%.

AJANTPHARM Financial Health — Key Ratios vs Industry Benchmarks

Ajanta Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 34.3% Industry Standard: 15%+ Above 15% Measures shareholder return efficiency
Operating Margin 31.0% Industry Standard: 20%+ Above 20% Indicates operational efficiency level
Asset Turnover Ratio 1.19x Industry Standard: 1.0x+ Above 1.0x Measures asset utilization efficiency

AJANTPHARM Cash Flow Quality — Operating & Free Cash Flow

Ajanta Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹529 Cr ₹315 Cr Positive Free Cash Flow 8/10
March 2025 ₹1,157 Cr ₹969 Cr Positive Free Cash Flow 8/10
March 2024 ₹785 Cr ₹785 Cr Positive Free Cash Flow 8/10
March 2023 ₹792 Cr ₹512 Cr Positive Free Cash Flow 8/10
March 2022 ₹562 Cr ₹525 Cr Positive Free Cash Flow 8/10